Table 3 Top 10 adverse effects (all grade) associated with gefitinib versus erlotinib
Adverse effects | Gefitinib group (event/total) | Erlotinib group (event/total) | RR (95% CI) | P value | Heterogeneity | |
|---|---|---|---|---|---|---|
I2 (%) | P value | |||||
Skin rash | 673/1099 | 650/944 | 0.83 (0.74–0.94) | 0.003 | 68 | 0.0009 |
Diarrhea | 298/999 | 273/745 | 0.83 (0.73–0.95) | 0.005 | 47 | 0.06 |
Nausea/Vomiting | 107/639 | 139/531 | 0.71 (0.32–1.57) | 0.4 | 74 | 0.002 |
Fatigue | 124/639 | 149/531 | 0.47 (0.23–0.95) | 0.04 | 81 | < 0.0001 |
Anorexia | 53/403 | 40/310 | 0.98 (0.40–2.42) | 0.97 | 78 | 0.001 |
Interstitial lung disease | 35/949 | 19/723 | 1.38 (0.78–2.44) | 0.26 | 0 | 0.65 |
Stomatitis | 12/260 | 29/169 | 0.29 (0.15–0.54) | 0.0001 | 24 | 0.27 |
Elevated liver enzymes | 366/931 | 264/680 | 1.16 (0.85–0.1.56) | 0.35 | 61 | 0.04 |
Infection | 45/686 | 23/466 | 1.53 (0.93–2.51) | 0.1 | 23 | 0.27 |
Neutropenia | 61/399 | 51/379 | 1.19 (0.85–1.66) | 0.32 | 0 | 0.55 |